M&A Deal Summary

SOBI Acquires CTI BioPharma

On May 10, 2023, SOBI acquired life science company CTI BioPharma for 1.7B USD

Acquisition Highlights
  • This is SOBI’s 3rd transaction in the Life Science sector.
  • This is SOBI’s largest (disclosed) transaction.
  • This is SOBI’s 2nd transaction in the United States.
  • This is SOBI’s 1st transaction in Washington.

M&A Deal Summary

Date 2023-05-10
Target CTI BioPharma
Sector Life Science
Buyer(s) SOBI
Deal Type Add-on Acquisition
Deal Value 1.7B USD

Target

CTI BioPharma

Seattle, Washington, United States
CTI is a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI BioPharma was founded in 1991 and is based in Seattle, Washington.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

SOBI

Stockholm 

, Sweden

Category Company
Founded 1939
Sector Life Science
Employees1,772
Revenue 22.1B SEK (2023)
DESCRIPTION

SOBI is an integrated biopharmaceutical company with an international market presence, developing and commercializing pharmaceuticals for patients with rare diseases. SOBI was founded in 1939 and is headquartered in Solna, Sweden.


DEAL STATS #
Overall 4 of 4
Sector (Life Science) 3 of 3
Type (Add-on Acquisition) 4 of 4
State (Washington) 1 of 1
Country (United States) 2 of 2
Year (2023) 1 of 1
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-09-30 Dova Pharmaceuticals

Durham, North Carolina, United States

Dova Pharmaceuticals, Inc. is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need. Dova Pharmaceuticals was founded in 2016 and is headquartered in Durham, North Carolina.

Buy $915M